Rosalie Luiten

Title: Rosalie Luiten: Innovator in Tumor Antigen Research

Introduction

Rosalie Luiten is a prominent inventor based in Brussels, Belgium. She has made significant contributions to the field of cancer research, particularly in the isolation of tumor antigens and cytotoxic T lymphocyte (CTL) clones. With a total of 4 patents to her name, Luiten's work has the potential to impact the diagnosis and treatment of various pathological conditions.

Latest Patents

One of her latest patents focuses on tumor antigens and CTL clones isolated by a novel procedure. This invention relates to the isolation of CTL clones that are specific for proteins of the MAGE family. The CTL clones have been isolated through successive steps of stimulation and testing of lymphocytes with antigen-presenting cells that present antigens derived from different expression systems. Additionally, her work includes nucleic acid molecules encoding antigenic peptides from MAGE molecules that bind to HLA. An example of such a nucleic acid molecule is one coding for the peptide GVYDGREHTV, which binds to HLA-A2. These innovations are crucial for advancing cancer diagnostics and therapies.

Career Highlights

Throughout her career, Rosalie Luiten has worked with esteemed organizations, including the Ludwig Institute for Cancer Research Limited. Her research has been pivotal in the field of immunology and cancer treatment, showcasing her dedication to improving patient outcomes.

Collaborations

Luiten has collaborated with notable colleagues such as Marie-Therese Duffour and Nathalie Demotte. These partnerships have further enriched her research and contributed to the advancement of cancer therapies.

Conclusion

Rosalie Luiten's innovative work in tumor antigen research exemplifies her commitment to advancing medical science. Her patents and collaborations highlight her significant role in the fight against cancer.